6月4日，诺和诺德盘中上涨3.12%，报43.94美元/股，成交额1.44亿美元。消息面上，制药板块集体走强，礼来涨4.05%、默沙东涨4.04%、施贵宝涨3.25%、辉瑞涨1.95%，诺和诺德跟随板块反弹，此前连续两个交易日回调后迎来修复。
此外，近期多重利好持续发酵：诺和诺德与合作伙伴Metabolic宣布阿联酋将成为美国以外首个获得口服版Wegovy的市场，临床试验显示口服版64周内平均减重17%；印度亦已批准Wegovy用于12岁及以上青少年群体，适应症拓展持续推进。司美格鲁肽前三季度销售额约254.62亿美元，同比增长24%，基本面支撑股价反弹。
（以上内容均基于市场公开消息，由程序或算法智能生成，仅作为股价异动提醒，不作为投资建议或交易依据。）
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.